Multiple clinical studies have showed that dual targeting VEGF and PD‐1/PD‐L1 pathways could significantly improve the clinical outcomes in metastatic renal cancer,20, 21 non‐small cell lung cancer,22, 23 and hepatocellular carcinoma.24 This evidence concerns the gene VEGFA and hepatocellular carcinoma.